As we previously characterized the emergence of the PD-1/PD-L1 inhibition as the “end of the beginning” of cancer immunotherapy [7], the exciting advances that are described in this review could very well represent the “beginning of the end” of non-selective cytotoxic chemotherapy. Here, PDCD1 is linked to cancer.